Literature DB >> 9626470

Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.

J Kos1, H J Nielsen, M Krasovec, I J Christensen, N Cimerman, R W Stephens, N Brünner.   

Abstract

The level of cathepsin B (Cat B) was determined in sera obtained preoperatively from 325 patients with colorectal cancer using an ELISA. Control sera from 90 healthy blood donors were analyzed. The levels of Cat B detected included all forms that were present in the sera, i.e., mature enzyme, precursor molecule, and enzyme-inhibitor complexes. The level of Cat B was significantly increased in sera of patients with colorectal cancer. The median level was 10.7 ng/ml versus 2.1 ng/ml in controls (P < 0.0001). A correlation between Cat B serum level and advanced Dukes' stage (P < 0.003) was found, whereas no associations have been found with age, sex, or level of carcinoembryonic antigen (CEA). In survival analysis, the patients with high serum Cat B experienced significantly lower survival probability. At the optimal cutoff value of 9.4 ng/ml, the relative hazard ratio was 1.8 (95% confidence interval, 1.1-2.8; P = 0.016) in the univariate Cox proportional hazards model. The median observation time was 4.4 years (range, 3.2-5.5 years). In multivariate analysis, Dukes' stage was the strongest prognostic variable, followed by age, whereas serum Cat B and CEA were not significant prognostic factors in this model, in accordance with their association with Dukes' stage. When the data for Cat B and CEA were combined, CEA-positive patients were further separated by Cat B into high- and low-risk groups. Patients with high serum levels of both molecules had significantly shorter survival (relative hazard ratio of 2.2; 95% confidence interval, 1.5-3.2; P < 0.0001), as compared with patients with low levels of both molecules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626470

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Andrzej Wincewicz; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

3.  Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1.

Authors:  Kanako Shibata; Yoshinari Yasuda; Ryo Kobayashi; Yuichi Ando; Tomoya Shimokata; Hideki Kamiya; Mutsuharu Hayashi; Shoichi Maruyama; Seiichi Matsuo; Makoto Nakao; Teruo Tsuchiya; Hitomi Teramachi
Journal:  Clin Exp Nephrol       Date:  2015-04-19       Impact factor: 2.801

Review 4.  Lysosomal enzymes, cathepsins in brain tumour invasion.

Authors:  Natasa Levicar; Tadej Strojnik; Janko Kos; Ricardo A Dewey; Geoffrey J Pilkington; Tamara T Lah
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

5.  Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.

Authors:  Qingyong Chen; Jun Fei; Lijun Wu; Zhongyong Jiang; Yuquan Wu; Yun Zheng; Guohua Lu
Journal:  Oncol Lett       Date:  2011-05-11       Impact factor: 2.967

Review 6.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

7.  Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis.

Authors:  J Kos; A Sekirnik; G Kopitar; N Cimerman; K Kayser; A Stremmer; W Fiehn; B Werle
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

8.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

9.  Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.

Authors:  Eva Kolwijck; Leon F A G Massuger; Chris M G Thomas; Paul N Span; Marta Krasovec; Janko Kos; Fred C G J Sweep
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-14       Impact factor: 4.553

10.  Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.

Authors:  László Herszényi; Fabio Farinati; Romilda Cardin; Gábor István; László D Molnár; István Hritz; Massimo De Paoli; Mario Plebani; Zsolt Tulassay
Journal:  BMC Cancer       Date:  2008-07-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.